Marotta Asset Management Cuts Position in Genmab A/S (NASDAQ:GMAB)

Marotta Asset Management trimmed its position in shares of Genmab A/S (NASDAQ:GMAB) by 5.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,793 shares of the company’s stock after selling 739 shares during the period. Marotta Asset Management’s holdings in Genmab A/S were worth $269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of GMAB. GAMMA Investing LLC raised its stake in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after buying an additional 3,880 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after buying an additional 1,413 shares in the last quarter. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. grew its position in Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after acquiring an additional 478 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

Shares of Genmab A/S stock traded down $0.08 during trading hours on Friday, hitting $22.11. The company’s stock had a trading volume of 249,218 shares, compared to its average volume of 750,186. The stock has a market cap of $14.63 billion, a price-to-earnings ratio of 21.47, a P/E/G ratio of 0.63 and a beta of 0.97. Genmab A/S has a twelve month low of $19.85 and a twelve month high of $31.97. The firm has a fifty day moving average of $21.32 and a 200-day moving average of $24.25.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the business earned $0.47 earnings per share. On average, sell-side analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GMAB. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, BMO Capital Markets restated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.